RESUMO
SAR studies of the substitution effect on the central phenyl ring of the biphenyl scaffold were carried out using anacetrapib (9a) as the benchmark. The results revealed that the new analogs with substitutions to replace trifluoromethyl (9a) had a significant impact on CETP inhibition in vitro. In fact, analogs with some small groups were as potent or more potent than the CF(3) derivative for CETP inhibition. Five of these new analogs raised HDL-C significantly (>20mg/dL). None of them however was better than anacetrapib in vivo. The synthesis and biological evaluation of these CETP inhibitors are described.
Assuntos
Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , Oxazolidinonas/farmacologia , Animais , Química Farmacêutica/métodos , HDL-Colesterol/metabolismo , Relação Dose-Resposta a Droga , Desenho de Fármacos , Humanos , Concentração Inibidora 50 , Camundongos , Camundongos Transgênicos , Modelos Químicos , Relação Estrutura-AtividadeRESUMO
The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Initial efforts aimed at engineering replacements for the aniline substructures in the benchmark molecule. Reversing the connectivity of the central aniline lead to a new class of 2-(4-carbonylphenyl)benzoxazoles. Structure-activity studies at the C-7 and terminal pyridine ring allowed for the optimization of potency and HDLc-raising efficacy in this new class of inhibitors. These efforts lead to the discovery of benzoxazole 11v, which raised HDLc by 24 mg/dl in our transgenic mouse PD model.
Assuntos
Benzoxazóis/química , Benzoxazóis/farmacologia , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , HDL-Colesterol/sangue , Animais , Desenho de Fármacos , Camundongos , Camundongos Transgênicos , Relação Estrutura-AtividadeRESUMO
The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Efforts focused on finding suitable replacements for the central piperidine with the aim of reducing hERG binding: a main liability of our benchmark benzoxazole (1a). Replacement of the piperidine with a cyclohexyl group successfully attenuated hERG binding, but was accompanied by reduced in vivo efficacy. The approach of substituting a piperidine moiety with an oxazolidinone also attenuated hERG binding. Further refinement of this latter scaffold via SAR at the pyridine terminus and methyl branching on the oxazolidinone led to compounds 7e and 7f, which raised HDLc by 33 and 27mg/dl, respectively, in our transgenic mouse PD model and without the hERG liability of previous series.
Assuntos
Benzoxazóis/química , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , HDL-Colesterol/metabolismo , Transativadores/metabolismo , Animais , Benzoxazóis/síntese química , Benzoxazóis/farmacologia , Concentração Inibidora 50 , Camundongos , Camundongos Transgênicos , Estrutura Molecular , Ligação Proteica/efeitos dos fármacos , Relação Estrutura-Atividade , Regulador Transcricional ERGRESUMO
We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy moiety with piperazinyl provided a more synthetically tractable lead, which upon optimization resulted in compound 4, an excellent inhibitor of cholesteryl ester transfer protein function with good pharmacokinetic properties and in vivo efficacy.
Assuntos
Acetanilidas/química , Benzoxazóis/química , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , HDL-Colesterol/sangue , Acetanilidas/síntese química , Acetanilidas/farmacocinética , Animais , Benzoxazóis/síntese química , Benzoxazóis/farmacocinética , Proteínas de Transferência de Ésteres de Colesterol/metabolismo , Camundongos , Camundongos Transgênicos , Relação Estrutura-AtividadeRESUMO
A series of 2-arylbenzoxazole inhibitors of the cholesterol ester transfer protein (CETP) is described. Structure-activity studies focused on variation of the substitution of the benzoxazole moiety. Substitution at the 5- and 7-positions of the benzoxazole moiety was found to be beneficial for CETP inhibition. Compound 47 was found to be the most potent inhibitor in this series and inhibited CETP with an IC(50) of 28nM.
Assuntos
Acetanilidas/química , Anticolesterolemiantes/química , Benzoxazóis/química , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , Acetanilidas/síntese química , Acetanilidas/farmacocinética , Administração Oral , Animais , Anticolesterolemiantes/síntese química , Anticolesterolemiantes/farmacocinética , Benzoxazóis/síntese química , Benzoxazóis/farmacocinética , Proteínas de Transferência de Ésteres de Colesterol/metabolismo , Camundongos , Relação Estrutura-AtividadeRESUMO
The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole beta-alkoxyamine 4 showed a desirable combination of in vitro potency (IC(50)=151 nM) and oral bioavailability in the mouse.
Assuntos
Benzoxazóis/síntese química , Benzoxazóis/metabolismo , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , Proteínas de Transferência de Ésteres de Colesterol/metabolismo , Álcoois/síntese química , Álcoois/metabolismo , Amidas/síntese química , Amidas/metabolismoRESUMO
A new class of CETP inhibitors was designed and prepared. These compounds are potent both in vitro and in vivo. The most active compound (12d) has shown an ability to raise HDL significantly in transgenic mouse PD model.
Assuntos
Benzilaminas/química , Compostos de Bifenilo/química , Carbamatos/química , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , Animais , Benzilaminas/síntese química , Benzilaminas/farmacologia , Compostos de Bifenilo/síntese química , Compostos de Bifenilo/farmacologia , Carbamatos/síntese química , Carbamatos/farmacologia , Proteínas de Transferência de Ésteres de Colesterol/metabolismo , Modelos Animais de Doenças , Desenho de Fármacos , Lipoproteínas HDL/metabolismo , Camundongos , Camundongos Transgênicos , Relação Estrutura-AtividadeRESUMO
Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C will decrease the likelihood of cardiovascular disease. Inhibition of cholesteryl ester transfer protein (CETP) has been shown to elevate HDL-C levels in human subjects. This letter describes the discovery of a novel and potent (<100 nM IC50 for the inhibition of CE transfer) CETP inhibitor scaffold containing an oxazolidinone core.
RESUMO
The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically, it was found that substitution of the 4-position with a methyl group with the cis-stereochemistry relative to the 5-aryl group afforded compounds with increased cholesteryl ester transfer protein (CETP) inhibition potency and a robust in vivo effect on increasing HDL-C levels in transgenic mice expressing cynomolgus monkey CETP.
Assuntos
Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , Oxazolidinonas/síntese química , Animais , Proteínas de Transferência de Ésteres de Colesterol/química , HDL-Colesterol/sangue , Humanos , Macaca fascicularis , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Oxazolidinonas/farmacocinética , Oxazolidinonas/farmacologia , Proteínas Recombinantes/química , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Cholesteryl ester transfer protein (CETP) is a serum component responsible for both cholesteryl ester and triglyceride trafficking between high-density lipoprotein (HDL) and the apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL). Several fluorescence-based assays that monitor these transfers have been reported, but to date such assays have suffered from a low signal/background (S/B) ratio and have been described for use only in relatively purified in vitro systems. We have modified the more advanced of these assays to incorporate a noninterfering, nondiffusable fluorescence quencher into previously described cosonicate particles, often referred to as microemulsions. This simple improvement resulted in particles that had an average threefold enhanced S/B window over particles without quenchers but that continued to show the essential properties of a catalytic assay, including catalysis to a single endpoint, excellent linearity with protein and particle concentration, and an appropriate sensitivity to inhibition. This reduced assay noise allowed the subsequent development of protocols for the direct measure of cholesteryl ester (CE) transfer activity resident in human and animal serum as well as the development of 384- and 3456-well screening protocols with good precision and accuracy. Thus, by expanding the dynamic response window of the assay, we have created an assay generalizable to many settings.